Indications
Contraindications
- Squamous Cell Lung Cancer: due to risk of hemorrhage
- Central Nervous System Metastases: due to risk of hemorrhage
Pharmacology
- Monoclonal Ab Which Binds To and Inhibits Vascular Endothelial Growth Factor (VEGF)
- Inhibits tumoral angiogenesis
Administration
Adverse Effects
Cardiovascular Adverse Effects
- Congestive Heart Failure (see Congestive Heart Failure, [[Congestive Heart Failure]])
- Epidemiology: mostly when bevacizumab is used in combination with anthracyclines, rasing question of true association
- Hypertension (see Hypertension, [[Hypertension]])
Gastrointestinal Adverse Effects
Hematologic Adverse Effects
- Increased Risk of Thromboembolic Disease (see Hypercoagulable States, [[Hypercoagulable States]])
- Epidemiology: 2-fold increased risk
- Physiology: may be due to vascular injury
- Thrombotic Microangiopathic Hemolytic Anemia (see Hemolytic Anemia, [[Hemolytic Anemia]])
- Microangiopathic Hemolytic Anemia (MAHA)
- Hypertension
- Renal Failure
Neurologic Adverse Effects
Pulmonary Adverse Effects
- Pulmonary Hemorrhage from Lung Cancer Tumor Necrosis
- Prognosis: fatalities have been reported
Other Adverse Effects
- Impaired Wound Healing
- Osteonecrosis of the Jaw
- Ovarian Failure
References